Medicine
Onpattro 10 mg/5 mL lipid complex injection
Onpattro 10 mg/5 mL lipid complex injection is a prescription medicine containing Patisiran for intravenous use, marketed by Alnylam Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store at 2°C to 8°C (36°F to 46°F). Do not freeze. If refrigeration is not…
Key facts
- Active ingredient (INN)
- Patisiran
- Brand
- Onpattro
- Strength
- 10 mg/5 mL
- Dosage form
- Lipid complex injection
- Route
- Intravenous
- Packs
- 1 vial of 5 mL
- Marketing authorisation holder
- Alnylam Pharmaceuticals
- Manufacturer
- Alnylam Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 2°C to 8°C (36°F to 46°F). Do not freeze. If refrigeration is not available, ONPATTRO can be stored at room temperature up to 25°C (up to 77°F) for up to 14 days. For storage conditions of ONPATTRO after dilution in the infusion bag, see Dosage and Administration.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N07XX12 Patisiran
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 August 2018
- Identifiers
- RxCUI 2053524, 2053529DailyMed set ID e87ec36f-b4b4-49d4-aea4-d4ffb09b0970NDC 71336-1000Application NDA210922
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 5 mL in 1 vial, single-dose | 71336-1000-1 | Alnylam Pharmaceuticals | 13 August 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Patisiran is a small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is available as lipid complex injection for intravenous use. MedsAcross supplies Patisiran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PatisiranFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Onpattro prescribing information (Alnylam Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Onpattro: European public assessment report (EPAR) · European Medicines Agency
Need Onpattro 10 mg/5 mL lipid complex injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.